If pancreatitis is suspected, stop taking Mounjaro until this has been excluded Right upper abdominal pain, fever, or yellowing of the skin/eyes , which could indicate gallbladder diseasean adverse effect associated with GLP-1-based therapies Persistent vomiting that prevents adequate fluid or medication intake Signs of dehydration including decreased urine output, extreme thirst, or lightheadedness Unexplained weight loss beyond expected therapeutic effects Symptoms of hypoglycaemia (low blood sugar) such as trembling, sweating, confusion, or palpitations, particularly if taking Mounjaro alongside insulin or sulphonylureas Seek immediate medical attention (call 999 or attend A&E) if you experience: Severe, unrelenting abdominal pain radiating to the back Signs of severe allergic reaction (anaphylaxis): difficulty breathing, facial swelling, or widespread rash Symptoms of diabetic ketoacidosis in insulin-treated patients: excessive thirst, frequent urination, nausea, vomiting, abdominal pain, confusion, or fruity-smelling breath (note: do not abruptly reduce insulin doses without medical supervision) For urgent but non-emergency advice when your GP is unavailable, contact NHS 111
Strbe S, Smoday IM, Krezic I, Kalogjera L, Vukovic V, Zizek H, et al
GLP-1 treatment typically starts curbing appetite within 1 to 4 weeks for most beginners
Nootropic effects
Best supplementation can be achieved by ingesting or injecting B12 on a regular basis
doi: 10.1210/jc.2018-00070 28 MarsoSPBainSCConsoliAEliaschewitzFGJodarELeiterLAet al
